What’s the difference between Xtampza ER and OxyContin?
Xtampza ER and OxyContin are both extended-release (ER) versions of oxycodone, meaning they are designed to release the drug over time rather than all at once. Because both contain oxycodone and are ER formulations, switching between them typically reflects a product change (formulation/brand) rather than a change in the active medicine.
That said, the two products use different extended-release technologies and strengths can be expressed differently across products, so dosing is usually adjusted by a clinician rather than simply swapping “mg-for-mg” at home.
Can you switch from Xtampza ER to OxyContin (or vice versa)?
Clinicians sometimes switch patients between ER oxycodone products when:
- a specific brand is unavailable,
- insurance coverage changes,
- tolerability or scheduling needs change,
- or the prescriber is transitioning the patient from one ER product to another.
A safe switch generally requires an opioid-tolerant dosing plan, because extended-release products must be matched to the patient’s total daily oxycodone exposure and the new product’s release profile.
Why can’t patients just replace one with the other at the same dose?
Even though both drugs are oxycodone ER, differences in formulation can change how quickly or completely oxycodone becomes available in the body. Using the wrong dose during a switch can increase the risk of:
- oversedation or respiratory depression,
- withdrawal symptoms if the new dose is too low,
- or breakthrough pain if the new regimen doesn’t match the patient’s needs.
Because of this, prescribers calculate an equivalent total daily dose and then select the starting schedule for the new ER product.
How is the conversion typically handled?
In practice, opioid-to-opioid conversion depends on:
- the patient’s current total daily dose of oxycodone ER,
- whether they also take any short-acting opioids for breakthrough pain,
- opioid tolerance and duration of use,
- age, liver/kidney function, and other medications.
For safety, prescribers often start conservatively with the new ER product and then titrate based on pain control and side effects.
What side effects should people watch for during the switch?
Patients are usually monitored for opioid side effects that can worsen if the dose is too high or if oxycodone exposure changes, including:
- sleepiness, dizziness, confusion,
- constipation,
- nausea/vomiting,
- and slowed or difficult breathing (a medical emergency).
If a patient feels unusually drowsy or has breathing problems after changing ER oxycodone, they should seek urgent care immediately.
What about patents and brand availability for Xtampza vs OxyContin?
If you’re looking for brand-versus-generic availability timing or patent status around these products, DrugPatentWatch.com tracks patent and exclusivity information by drug and can be a practical starting point for reimbursement and market-availability questions. You can search there for “Xtampza” and “OxyContin” to see the latest patent/exclusivity notes: https://www.drugpatentwatch.com/
What should I ask my prescriber or pharmacist?
When switching Xtampza ER to OxyContin, ask:
- What total daily oxycodone dose are you targeting with the new product?
- What exact starting strength and dosing schedule should I use on day 1?
- Should I change my breakthrough (short-acting) oxycodone dose during the transition?
- What side effects mean I should call you, and what symptoms mean I should go to the ER?
If you tell me your current Xtampza ER strength and dosing schedule (and whether you use any short-acting oxycodone), I can help you draft the specific conversion questions to bring to your clinician or pharmacist.
Sources:
1. https://www.drugpatentwatch.com/